Amicus Therapeutics, Inc. (FOLD) Announces Fourth Quarter and Year End 2008 Financial Results Release Date
…Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease.

These are articles from my google alerts and other interesting articles I find about Gaucher’s Disease and Cerezyme in the news. There is so much that I need to learn, and I just don’t have the time yet, as we are trying to get Hannah’s medical treatment and insurance situation figured out. I’m posting these here mostly for me to keep track of and if anyone else is interested in learning what is new on the research front.

• First Patient Enrolled In Open-Label, Switchover Trial Of PrGCD For The Treatment Of Gaucher Disease
• Group Charged With ‘Playing God’ Over Genetic Testing
• Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs
• New treatment has Plymouth boy with rare genetic disorder beating the odds
• Protalix BioTherapeutics – Gaucher disease case study” will be the keynote presentation
• Genetic Diseases and Dysmorphic Syndromes Gaucher’s Disease